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Background: Gastric ulceration is highly prevalent in horses, and there is a large commercial market for feed-additives
and non-licenced products that claim effect for prevention and treatment of gastric ulceration. ImproWinW has been
used as a feed additive in horses with anecdotal evidence that it may have some positive effects on gastric ulceration.
The aim of this study was to investigate the effect of ImproWinW treatment on spontaneously occurring gastric ulcers
of the squamous mucosa in Standardbred and Coldblooded trotting racehorses.
The study was performed as a randomised, double-blinded, single centre study with stratified semi cross-over design with
breed as stratification factors. The horses were clinically and endoscopically examined prior to start and after three weeks
of treatment. The ulcerations were scored in accordance with Equine Gastric Ulcer Council (EGUC) recommendations on
a 5 point scale and on a 10 cm Visual Analogue Scale (VAS). The patients were responder-classified after 3 weeks.
Responders in need of ulcer treatment were randomly allocated to 2 or 4 weeks of additional treatment. Non-responders
to placebo were crossed to ImproWinW.
Results: The 5-point EGUC score and VAS recorded score was significantly reduced (P≤ 0.01) in both groups after
3 weeks of treatment. From 3 weeks to the end of treatment the score was further significantly reduced in the
ImproWinW group (P≤ 0.05).
At the end of treatment, 78% in the ImproWinW group and 54.8% in the placebo group were classified as responders.
The difference was significant (P =0.04).
Conclusions: ImproWinW may aid the healing process of ulcers of the gastric squamous mucosa of trotters.
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Gastric ulceration is frequent in all types of horses. Gastric
ulcers were first recognised as an important disease of
foals [1]. It has later been shown that gastric ulceration is
highly prevalent in mature horses, especially those ex-
posed to high levels of training and intensive management
practices [2].
The prevalence of gastric ulcers reported in mature
horses varies between populations and ranges from 58 to
93% [2-5]. In Standardbred trotters the prevalence has
been found to be 44 to 70% [6,7] and the prevalence was
significantly higher in active racing horses compared to
those at rest.
The proton pump inhibitor omeprazole has been found
safe and highly efficient in both treating and preventing* Correspondence: Ingunn.risnes@rikstoto.no
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distribution, and reproduction in any mediumrecurrence of gastric ulcers in horses [8-11] at dose ranges
from 1–4 mg/kg. Comparison of omeprazole and hista-
mine 2 antagonists shows superior effect of omeprazole
[12,13]. Other drugs used to enhance gastric mucosal pro-
tection, such as sucralfate and aluminium containing ant-
acids, have shown inferior results or lack documentation
of effectiveness in treatment of ulcerations of the equine
squamous mucosa [14-16].
Calcium carbonate additives or alfalfa hay may reduce
the ulcerogenic effect of volatile fatty acids from high
starch diets and has been suggested as part of a preventive
strategy. Pectin-lecithin complex has shown a possible
positive effect on healing of naturally occurring gastric ul-
cers in horses [17,18]. However, the same product failed to
prevent development of gastric ulcers in a group of feed
deprived ponies [19]. Compounds containing antacids
have shown variable effects and seem efficient in normal-
izing the pH only for a short period of time [20].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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without requiring the continued administration of costly
pharmaceutical agents and issues with withdrawal times
would be highly desirable.
ImproWinWa consists of salts of organic acids (SOC) in
combination with B-vitamins and has been used in horses
in Norway as a feed additive with anecdotal evidence that
it may have some positive effects on gastric ulceration.
The aim of this study was to investigate the effect and
benefit of ImproWinW treatment in spontaneously oc-
curring gastric ulcers of the squamous mucosa in Stand-
ardbred and Coldblooded trotting racehorses.
Methods
Materials
The study population consists of Norwegian Coldblooded
and Standardbred trotting racehorses past the age of 3 years
having verified gastric ulceration of the squamous mucosa.
The Intention-To-Treat (ITT) material consists of 78
horses with endoscopically verified ulcers in the nongland-
ular mucosa of severity grade 2 or above on a scale from
0–4 [21]. Eleven horses, four in the ImproWinW group
and seven in the placebo group, were blindly classified as
violators to the protocol either due to use of other ulcer
treatment or change in the feeding procedure during the
study period. Of the remaining 67 horses included in the
study 14 mares, 6 stallions and 16 geldings were allocated
to ImproWinW and 12 mares, 5 stallions and 14 geldings
to similar-looking same-volume placebo. The two treat-
ment groups were found clinically equal regarding distri-
bution of gender and breed. The mean age in the
ImproWinW group was 5.3 years (range 2–8) and in the
placebo group 5.8 years (range 3–13). No significant inter-
action was detected between the treatment groups, gender,
breed and age (P > 0.21).
Design and randomisation
The study was performed as a randomised, double-
blinded and single centre study with stratified semi cross-
over design [22]. Coldblooded and Standardbred trotters
defined the study strata. Within stratum the horses were
allocated 1:1 to ImproWinW or similar-looking same-
volume placebo for three weeks by block randomisation
with a fixed block size of eight [23]. Based on the improve-
ment of 1 grade or more on the 5 point ulcer scale de-
scribed below, the patients were classified as responder or
non-responder to the given treatment. Patients classified
as responder to the given three weeks treatment continued
on the same treatment for an additional two or four weeks
and endoscopically examined again. Patients in which the
ulcers were grade 0 or 1 were considered cured and dis-
continued the study. Non-responders were blindly crossed
to ImproWinW or proton pump inhibitors and treated
conventionally in the clinic.Study procedure
All the included patients were recruited via Rikstotoklinik-
ken Bjerke. Horses fulfilling the inclusion and exclusion cri-
teria were included in the study when written consent from
the owner and/or the trainer was given. Owners/trainers
were asked to fill out a questionnaire recording any change
in training/stabling/feeding between examinations.
The horses were clinically examined and the ulcer endo-
scopically verified and scored prior to start of treatment
by one investigator (IRH). Prior to gastroscopy, food was
withheld for 18–24 hours. Water was freely accessible up
to the time of examination. A 3.3 meter videoendoscopec
was passed and the stomach manually insufflated with air
through a garden spraypump system attached to the bi-
opsy channel in the endoscope until the internal stom-
ach folds appeared flattened. Feed material adherent to
the non-glandular mucosa was flushed away with water
through a separate garden spraypump system so the entire
non-glandular portion of the stomach could be visualised,
including the greater curvature, the lesser curvature and
the dorsal fundus. The number and the degree of ulcers of
the non-glandular mucosa were recorded in accordance
with the Equine Gastric Ulcer Council (EGUC) recom-
mendations [21]. The glandular area of the stomach was
not evaluated for the purpose of this study. Additionally,
the degree of ulceration was recorded on a 10 cm Visual
Analogue Scale (VAS) by the investigator after each endo-
scopic examination. The VAS is a subjective overall score
of the ulcer severity marked on a continuous scale from
0–10, where 0 is no ulceration and 10 is the maximum
score. This scale is validated in humans [24] but not in
horses. In accordance with the prerandomisation code, the
treatment was started the same day as the initial examin-
ation. The treatment dose of ImproWinW and placebob was
40 grams (50 ml) powder once a day mixed in the feed with
water. In the few cases where the horses refused to eat the
powder mixed into the food, the powder was mixed with
water into a paste and given in a syringe by mouth. The
horses were all trained as normal during the treatment
period and they were allowed to participate in races.
After three weeks of treatment a second endoscopic in-
vestigation was performed by the same endoscopist and the
degree of ulceration was recorded in the same way as previ-
ously explained. Responders still in need of ulcer treatment
were randomly allocated to either 2 or 4 weeks continuous
treatment with the same regime and again endoscopically
investigated. Patients with unchanged or increased degree
of ulceration after three weeks of treatment were classified
as non-responders to the given regime. Non-responders to
placebo were crossed to ImproWinW treatment for either
two or four weeks and finally endoscopically examined.
The non-responders to ImproWinW were all crossed to
proton pump inhibitor therapy and treated conventionally
in the clinic, but not included in the study.
Table 1 The degree and change in degree of ulceration
from start to three week and to end of treatment
Treatment Weeks of
recording
Degree of
ulceration
Recorded degree
of ulceration at start
Total
2 3 4
ImproWin® 3 weeks 0 5 3 4 12
1 1 4 0 5
2 3 6 1 10
3 0 4 1 5
4 1 1 2 4
Total 10 18 8 36
End of
treatment
0 6 10 6 22
1 2 3 0 5
2 1 1 0 2
3 0 3 0 3
4 1 1 2 4
Total 10 18 8 36
Placebo 3 weeks 0 7 2 0 9
1 3 0 1 4
2 2 2 3 7
3 2 8 0 10
4 0 0 1 1
Total 14 12 5 31
End of
treatment
0 10 4 1 15
1 0 0 1 1
2 1 0 1 2
3 3 8 0 11
4 0 0 2 2
Total 14 12 5 31
The degree and change in degree of ulceration from start to three week and
to end of treatment recorded on the 5 point scale [21]. The numbers bolded
indicate the number of horses which were unchanged after the given
treatment. The numbers above the bolded numbers indicate horses improved
after the given treatment and the numbers below indicate the number of
horses that had a worsening of ulcer score in that treatment period.
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Assumed continuously distributed variables are expressed
by mean values with 95% confidence interval constructed
by using the Student procedure [25]. Confidence intervals
for prevalence were constructed using simple binomial se-
quences [26]. Discrete distributed variables are expressed
in contingency tables [26]. All tests are performed two-
tailed with a significance level of 5%. Analysis of Variance
(ANOVA) with the initial degree of ulcer as covariate was
performed for changes within and comparison between
groups [27] on the assumed continuously distributed vari-
able. Changes and comparison on discrete variables were
performed by Contingency Table Analysis [26].
With a significance level of 5%, a power of 90% and a
clinical relevant difference between the groups of one
time the standard deviation, 32 horses in each group
had to be included.
Results
No significant difference (P = 0.33) was found at the start
between the two treatment groups regarding degree of ul-
ceration recorded on the equine gastric ulceration syn-
drome (EGUS) recommended scale. During the first three
weeks of treatment, the ulcer score was reduced for 25 of
the 36 (69.4%) ImproWinW treated horses and for 18 of
the 31 (58.1%) in the placebo group. The reductions were
found significant in both groups (P < 0.01).
At the start of treatment in the ImproWinW group, 10
horses had grade 2, 18 horses had grade 3 and 8 horses
had grade 4 ulcerations (Table 1). After 3 weeks treatment,
11 horses were unchanged or worse, 12 were graded 0, five
graded 1, ten graded 2, five graded 3 and four horses were
graded 4. Consequently, an improvement of 1 grade was
seen in eight horses, 2 grades in ten horses, 3 grades in
three horses and 4 grades in four horses in the Impro-
WinW group. After 3 weeks treatment in the placebo
group, 13 horses were unchanged or worse. An improve-
ment of 1 grade was seen in five horses, 2 grades in ten
horses and 3 grades in three horses. No horse had an im-
provement of 4 grades in the placebo treated group. No
significant difference (P = 0.36) was detected between the
groups on ulcer score after three weeks of treatment. From
three weeks to end of treatment in the ImproWinW group
the ulcer score was found to be reduced for 12 horses and
increased in one. In the placebo group, six horses had a re-
duced score and two had an increased score during the
same period. The reduction of ulcer score in the Impro-
WinW group was found significant (P < 0.01) but not in the
placebo group (P = 0.15). The ulcer score was found sig-
nificantly lower in the ImproWinW group compared to
placebo group at the end of treatment (P ≤ 0.05).
The two treatment groups were found comparable at
start of treatment (P = 0.37) regarding the degree of ul-
ceration recorded on a 10 cm VAS (Figure 1). In theImproWinW group, the ulceration was significantly re-
duced (P < 0.01) from 5.0 (95% CI: 4.4 – 5.7) to 2.4 (95%
CI:1.6 – 3 .3) after 3 weeks of treatment and further to
1.6 (95% CI: 0.7 – 2.6) at the end of treatment (P = 0.02).
A significant reduction from 4.6 (95% CI: 4.0 – 5.2) to 2 .8
(95% CI: 1.9 – 3.7) was also detected in the placebo group
(P < 0.01). A further reduction to 2.6 (95% CI: 1.7 – 3.5) at
the end of treatment in the placebo group was not found
significant. The total mean reduction of 3.4 (95% CI: 2.3 –
4.4) in the ImproWinW group was found significant larger
than the comparable reduction of 2.0 (95% CI: 1.0 – 3.0)
in the placebo group (P ≤ 0.05). The mean percent reduc-
tion in the VAS recorded degree of ulceration in the
ImproWinW group was found to be 68.2% (95% CI: 49.3 –
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The difference was found significant (P ≤ 0.05).
After three weeks of treatment, 69.4% of the horses in
the ImproWinW group and 58.1% in placebo group were
classified as responders to the given treatment (Table 2).
The difference was not found significant (P = 0.48). Thir-
teen of the patients in the placebo group were classified as
non-responders and 11 were crossed to four week Impro-
WinW treatment. Of these 11 horses, six were classified as
responder to the active treatment. In the placebo group,
18 responders and two non-responders continued the
same treatment and 17 of these were classified as re-
sponders at the end of treatment. At the end of treatment,
54.8% of the horses in the placebo group and 78% in the
ImproWinW group were classified as responders. The dif-
ference was significant (P = 0.04).
Discussion
The significant improvement in degree of ulceration
score in the placebo group (58.1%) found after 3 weeks
of treatment was higher than reported in previous stud-
ies. Spontaneous improvement rates of 32% compared to
99% improvement in horses treated with omeprazole
were found after 28 days in a similar study. The overall
healing rate was 8.9% and 87% respectively in the con-
trol and omeprazole treated groups in the same study
[11]. In that study the personnel that administered the
medication was not able to observe the examination.
Another study evaluating omeprazole in the treatment
and prevention of gastric ulceration in racehorses dem-
onstrated an improvement in ulcer score of 48% after
13 days, 42% after 20 days and 32% after 27 days in the
control group [9]. In this study all the horses wereFigure 1 Degree of ulceration recorded on 10 cm Visual
Analogue Scale (VAS). The degree of ulceration recorded on 10 cm
VAS from start to three week and to end of treatment. The results are
expressed as mean values with 95% confidence interval in brackets.reported to be treated equally regarding feed and manage-
ment. The healing rates in the control groups were 4, 8
and 4% respectively. Treatment with omeprazole at 4 mg/
kg resulted in 78% healing rates after 28 days, while 92%
were significantly improved.
Environmental factors such as feed, training/exercise
and housing are well known to influence development and
healing of gastric ulcers in horses. All owners or trainers
were told the results of the gastroscopy in our study. Al-
though they were instructed not to perform any differ-
ences in feeding or training regimes, it is reasonable to
assume that a significant proportion did instigate changes
that would very likely influence the development and heal-
ing of the ulcers. Due to the blinding of the treatment,
these changes have to be assumed equal in the two groups.
It was decided to keep these variables uncontrolled due to
the difficulty in controlling exactly what the owners and
trainers were feeding the horses.
Despite the lack of significant difference in prevalence of
responders between the two treatment groups after 3 weeks,
there was a significant different at end of treatment in favor
of the ImproWinW group. This difference is based on the
assumption that horses not responding to treatment after
3 weeks would still be non-responders at the end of treat-
ment. All non-responders to placebo were crossed to
ImproWinW with more than 50% response to treatment.
On the contrary, the three horses that did not respond to
ImproWinW were classified as responders at the end of
treatment, even though these 3 horses should have been
crossed to proton pump inhibitors. This would have given
an advantage for the ImproWinW group end results.
The non-responders to placebo after 3 weeks were
switched to ImproWinW for either 2 or 4 weeks. The ob-
tained response rate was lower than the initial response
rate in the ImproWinW group after 3 week.
The length of ImproWinW treatment seems to have an
impact on the response rate, with lowest prevalence after
2 and highest after 7 weeks of treatment. The improve-
ment of 4 grades was seen in four horses after 3 weeks
and six horses at the end of treatment in the ImproWinW
group. Comparatively, an improvement of 4 grades wasTable 2 Classification of responders after 3 weeks and at
the end of treatment
Treatment
period
a) ImproWinW/
ImproWinW
(n = 36)
b) Placebo/
ImproWinW
(n = 11)
c) Placebo/
Placebo
(n = 31/n = 20)
3 weeks 25/36 0/11 18/31
69.4 (51.9 – 83 .7) 0.0 (0.0 – 28.5) 58.1 (40.0 - 74.1)
End of
treatment
28/36 6/11 17/31
77.8 (60.9 – 89–9) 54.6 (23.4 – 83.3) 54.8 (34.7 – 73.0)
Classification of responders after 3 weeks and at the end of treatment in the
groups given a) Only ImproWinW b) Placebo and ImproWinW the last part and
c) Only placebo. The results are expressed as number of responders and
percent responders with 95% confidence interval.
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and in only one horse at the end of treatment.
A few trainers/owners in our study reported that the
feeding and environment were changed significantly and
these were classified as violators and excluded from the
study. The classification of violators was performed blindly
and it is believed likely that change in management and
feeding would be equally reflected in both treatment
groups. The study was performed double-blinded, but it is
still possible that the trainers and owners were able to
identify the treatment given due to some differences in
smell and color. This could also influence the obtained re-
sults. Many studies focus on the incidence of EGUS in
horses under different management, exercise and feeding
regimes [20,28-34]. Part of the spontaneous improvement
may be due environmental changes and factors and natural
healing. We were unable to separate these factors in our
study since there was no attempt to standardise manage-
ment and feeding protocols.
Salts of organic acids (SOC) have been used as a growth
promoter in pigs and research in this species has found
that SOC influence the bacteria in the proximal gastro-
intestinal tract in vitro [35,36] without negative effect on
the stomach lining [37]. The potential acidifying effect of
the use of SOC on horses’ gastric pH would obviously be a
concern when using these products to treat or prevent
EGUS. Although it is generally considered that dietary or-
ganic acids or their salts lower gastric pH, this has been
difficult to demonstrate [38]. When SOC are added into
an acidic environment, the solution will still be acidic but
pH will be slightly higher [39] and these compounds may
therefore act as a buffer of strongly acidic solutions such
as in the stomach. It is possible that the adding of an or-
ganic acid reduce the parietal acid secretion in the stom-
ach although the precise mechanism is not known.
The influence of these SOC-containing products on
the stomach pH has not been measured in horses, butFigure 2 Agreement on ulcer severity between Visual Analogue Scale
[21] and 10 cm VAS at the start and after 3 weeks of treatment. The results
confidence intervals within each ulcer grade.measurements in the caecum after feeding SOC to pigs
showed increase in pH compared to the pH in control
pigs [40]. In addition, several investigations have shown
that these products have a strong bactericidal effect
without significantly decreasing the pH values in the
gastrointestinal tract [35].
ImproWinW is well documented to inhibit pathogenic
bacteria in vitro, including Helicobacter and other bacteria
such as Escherichia coli [36]. Helicobacter-like DNA was
found in the gastric mucosa of horses with gastric ulcera-
tions [41], but so far there have been no conclusive findings
of a possible pathogenic link between presence of Helico-
bacter-like DNA and clinical manifestation of EGUS. Bac-
terial colonization by Gram negative bacteria in established
gastric ulcerations in rats has been shown to delay healing
while Lactobacillus colonization had a protective effect in
the same study [42]. Bacteria have also been found to ex-
acerbate mucosal injury in ulceration in the stomach or
small intestine induced by non-steroid anti-inflammatory
drugs [43]. Organic acids are believed to enter the microbial
organism in the undissociated form and dissociate in the
more alkaline cell interior, causing acidification of the cyto-
plasm and inhibition of metabolism. This effect is more
pronounced in the acid environment of the stomach com-
pared to the less acidic small intestine environment [36].
Bacteria, including E. coli, were cultured from equine sto-
machs [3] and it is possible that ImproWinW has a benefi-
cial effect on healing of gastric ulcers by reducing the
negative effect of bacterial colonization.
Another possible harmful effect caused by the presence
of pathogenic bacteria in the stomach is production of
volatile fatty acids (VFAs) and lactic acids from fermenta-
tion of soluble carbohydrates. VFAs and HCl have been
shown to penetrate the gastric mucosa at low pH and dis-
rupt cellular transport and cause cell swelling, cell death
and ulceration in vitro [44]. However, the bactericidal ef-
fect of ImproWinW in EGUS in horses remains unclear.(VAS) and 5 point scale. Ulcer severity recorded on 5 point scale
recorded on the VAS are expressed as mean values with 95%
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score after 3 weeks of treatment in both groups. The re-
duction in degree of ulceration from start to end of treat-
ment was found significantly larger in the ImproWinW
group compared to the placebo group, both with the 5
point scale and VAS. Comparison of the results obtained
by using the 5 point EGUC recommended scale and the
VAS detected a surprisingly linear relation (Figure 2). This
is probably because the scoring was always performed by
the same operator, with several operators the deviation
would increase. Assuming these important limitations, it
appears that VAS can give important additional informa-
tion outside the 5 point scale when using only one oper-
ator. With a five point fixed scale a large number of
patients would be needed to discover a difference. By
using VAS we were able to detect smaller differences with
a limited number of patients. Based on clinical trials in hu-
man, the VAS in evaluation of mucosal lesions is recom-
mended [24] but has not been validated in horses. To
evaluate this scoring system one would need to design a
separate study using more than one evaluator. It may be
more appropriate to use as a VAS scale for grading glan-
dular ulcerations (as in humans) where the ulcers tend to
be less variable in appearance.
The use of ImproWinW has not been validated against
the use of proton pump inhibitors. However, issues with
withdrawal times and cost of treatment with omeprazole
are of practical concern when treating ulcers in the non-
glanduar mucosa in racehorses. It is the opinion of the au-
thors that ImproWinW may have a place in treating and
possibly preventing these ulcers in horses while racing
since the supplement is allowed to use while racing in
Norway at the time of writing. Our results suggest that
treatment rates improve with longer periods of treatment,
however, response rate according to weeks of treatment
was not analysed separately in this study because there
were too few horses in each group and further studies
would be necessary to evaluate this.
Conclusion
ImproWinW seems to have a positive effect on ulcer
healing and adds benefit to the healing of gastric ulcers
in the squamous mucosa in horses on top of manage-
ment changes and placebo effect.
End notes
aImproWinW: HCOONa (Sodium formate), Ca(HCOO)2
(Calcium formate), C4H2FeO4 (Iron fumarate), C19H19N7O
(Folic acid), C63H88CoN14O14P ( Cobalamin), C8H11NO3
(Pyridoxine). Approx. pH of dry powder: 10. Vitality
Innovation, Oslo, Norway.
bPlacebo: icing sugar, paprikapowder (tasteless/tastepoor)
and turmeric.
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